Esmirtazapine
Esmirtazapine is a drug which was under development by Organon for the treatment of insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the --enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors. As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.
